BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 28672102)

  • 41. Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer.
    Guo X; Zhu SX; Brunner AL; van de Rijn M; West RB
    Breast Cancer Res; 2013 Dec; 15(6):R117. PubMed ID: 24342436
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Separation of breast cancer and organ microenvironment transcriptomes in metastases.
    Alzubi MA; Turner TH; Olex AL; Sohal SS; Tobin NP; Recio SG; Bergh J; Hatschek T; Parker JS; Sartorius CA; Perou CM; Dozmorov MG; Harrell JC
    Breast Cancer Res; 2019 Mar; 21(1):36. PubMed ID: 30841919
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A genomic ruler to assess oncogenic transition between breast tumor and stroma.
    Dhage S; Ernlund A; Ruggles K; Axelrod D; Berman R; Roses D; Schneider RJ
    PLoS One; 2018; 13(10):e0205602. PubMed ID: 30325954
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Podoplanin increases the migration of human fibroblasts and affects the endothelial cell network formation: A possible role for cancer-associated fibroblasts in breast cancer progression.
    Suchanski J; Tejchman A; Zacharski M; Piotrowska A; Grzegrzolka J; Chodaczek G; Nowinska K; Rys J; Dziegiel P; Kieda C; Ugorski M
    PLoS One; 2017; 12(9):e0184970. PubMed ID: 28938000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
    Brodsky AS; Xiong J; Yang D; Schorl C; Fenton MA; Graves TA; Sikov WM; Resnick MB; Wang Y
    BMC Cancer; 2016 Apr; 16():274. PubMed ID: 27090210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
    Cheng Q; Chang JT; Gwin WR; Zhu J; Ambs S; Geradts J; Lyerly HK
    Breast Cancer Res; 2014 Jul; 16(4):407. PubMed ID: 25060555
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
    De Brot M; Rocha RM; Soares FA; Gobbi H
    Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Action of Discoidin Domain Receptor 2 in Basal Tumor Cells and Stromal Cancer-Associated Fibroblasts Is Critical for Breast Cancer Metastasis.
    Corsa CA; Brenot A; Grither WR; Van Hove S; Loza AJ; Zhang K; Ponik SM; Liu Y; DeNardo DG; Eliceiri KW; Keely PJ; Longmore GD
    Cell Rep; 2016 Jun; 15(11):2510-23. PubMed ID: 27264173
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CHEK2 represses breast stromal fibroblasts and their paracrine tumor-promoting effects through suppressing SDF-1 and IL-6.
    Al-Rakan MA; Hendrayani SF; Aboussekhra A
    BMC Cancer; 2016 Aug; 16():575. PubMed ID: 27484185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Subtype-specific prognostic impact of different immune signatures in node-negative breast cancer.
    Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Elger T; Krajnak S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
    Breast Cancer Res Treat; 2017 Sep; 165(2):293-300. PubMed ID: 28585074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor-Associated Stromal Cellular Density as a Predictor of Recurrence and Mortality in Breast Cancer: Results from Ethnically Diverse Study Populations.
    Abubakar M; Zhang J; Ahearn TU; Koka H; Guo C; Lawrence SM; Mutreja K; Figueroa JD; Ying J; Lissowska J; Lyu N; Garcia-Closas M; Yang XR
    Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1397-1407. PubMed ID: 33952648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer.
    Li CI; Zhang Y; Cieślik M; Wu YM; Xiao L; Cobain E; Tang MC; Cao X; Porter P; Guenthoer J; Robinson DR; Chinnaiyan AM
    Clin Cancer Res; 2021 Jun; 27(11):3079-3093. PubMed ID: 33753452
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Human Organotypic Microfluidic Tumor Model Permits Investigation of the Interplay between Patient-Derived Fibroblasts and Breast Cancer Cells.
    Truong DD; Kratz A; Park JG; Barrientos ES; Saini H; Nguyen T; Pockaj B; Mouneimne G; LaBaer J; Nikkhah M
    Cancer Res; 2019 Jun; 79(12):3139-3151. PubMed ID: 30992322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study.
    Kuijer A; Schreuder K; Elias SG; Smorenburg CH; Rutgers EJ; Siesling S; van Dalen T
    Public Health Genomics; 2016; 19(5):276-81. PubMed ID: 27508402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single-cell analysis reveals the pan-cancer invasiveness-associated transition of adipose-derived stromal cells into COL11A1-expressing cancer-associated fibroblasts.
    Zhu K; Cai L; Cui C; de Los Toyos JR; Anastassiou D
    PLoS Comput Biol; 2021 Jul; 17(7):e1009228. PubMed ID: 34283835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.